354 related articles for article (PubMed ID: 31734097)
1. An educate, test and treat model towards elimination of hepatitis C infection in Egypt: Feasibility and effectiveness in 73 villages.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2020 Apr; 72(4):658-669. PubMed ID: 31734097
[TBL] [Abstract][Full Text] [Related]
2. An educate, test, and treat programme towards elimination of hepatitis C infection in Egypt: a community-based demonstration project.
Shiha G; Metwally AM; Soliman R; Elbasiony M; Mikhail NNH; Easterbrook P
Lancet Gastroenterol Hepatol; 2018 Nov; 3(11):778-789. PubMed ID: 30030068
[TBL] [Abstract][Full Text] [Related]
3. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia.
Averhoff F; Shadaker S; Gamkrelidze A; Kuchuloria T; Gvinjilia L; Getia V; Sergeenko D; Butsashvili M; Tsertsvadze T; Sharvadze L; Zarkua J; Skaggs B; Nasrullah M
J Hepatol; 2020 Apr; 72(4):680-687. PubMed ID: 31811882
[TBL] [Abstract][Full Text] [Related]
4. Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals.
Shiha G; Soliman R; Mikhail NNH; Easterbrook P
J Hepatol; 2021 Feb; 74(2):303-311. PubMed ID: 32931878
[TBL] [Abstract][Full Text] [Related]
5. Towards hepatitis C virus elimination: Egyptian experience, achievements and limitations.
Omran D; Alboraie M; Zayed RA; Wifi MN; Naguib M; Eltabbakh M; Abdellah M; Sherief AF; Maklad S; Eldemellawy HH; Saad OK; Khamiss DM; El Kassas M
World J Gastroenterol; 2018 Oct; 24(38):4330-4340. PubMed ID: 30344418
[TBL] [Abstract][Full Text] [Related]
6. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Waked I; Shiha G; Qaqish RB; Esmat G; Yosry A; Hassany M; Soliman R; Mohey MA; Allam N; Zayed N; Asselah T; Hall C; Redman R; Mobashery N; Doss W
Lancet Gastroenterol Hepatol; 2016 Sep; 1(1):36-44. PubMed ID: 28404110
[TBL] [Abstract][Full Text] [Related]
7. Prevalence of occult hepatitis C virus infection in patients who achieved sustained virologic response to direct-acting antiviral agents.
Yousif MM; Elsadek Fakhr A; Morad EA; Kelani H; Hamed EF; Elsadek HM; Zahran MH; Fahmy Afify A; Ismail WA; Elagrody AI; Ibrahim NF; Amer FA; Zaki AM; Sadek AMEM; Shendi AM; Emad G; Farrag HA
Infez Med; 2018 Sep; 26(3):237-243. PubMed ID: 30246766
[TBL] [Abstract][Full Text] [Related]
8. Systematic overview of hepatitis C infection in the Middle East and North Africa.
Chaabna K; Cheema S; Abraham A; Alrouh H; Lowenfels AB; Maisonneuve P; Mamtani R
World J Gastroenterol; 2018 Jul; 24(27):3038-3054. PubMed ID: 30038471
[TBL] [Abstract][Full Text] [Related]
9. Excess mortality rate associated with hepatitis C virus infection: A community-based cohort study in rural Egypt.
Mostafa A; Shimakawa Y; Medhat A; Mikhail NN; Chesnais CB; Arafa N; Bakr I; El Hoseiny M; El-Daly M; Esmat G; Abdel-Hamid M; Mohamed MK; Fontanet A
J Hepatol; 2016 Jun; 64(6):1240-6. PubMed ID: 26921686
[TBL] [Abstract][Full Text] [Related]
10. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia.
Tsertsvadze T; Gamkrelidze A; Nasrullah M; Sharvadze L; Morgan J; Shadaker S; Gvinjilia L; Butsashvili M; Metreveli D; Kerashvili V; Ezugbaia M; Chkhartishvili N; Abutidze A; Kvaratskhelia V; Averhoff F
BMC Infect Dis; 2020 Jan; 20(1):30. PubMed ID: 31924172
[TBL] [Abstract][Full Text] [Related]
11. Decentralised hepatitis C testing and treatment in rural Cambodia: evaluation of a simplified service model integrated in an existing public health system.
Zhang M; O'Keefe D; Craig J; Samley K; Bunreth V; Jolivet P; Balkan S; Marquardt T; Dousset JP; Le Paih M
Lancet Gastroenterol Hepatol; 2021 May; 6(5):371-380. PubMed ID: 33743883
[TBL] [Abstract][Full Text] [Related]
12. Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention.
Ayoub HH; Abu-Raddad LJ
J Viral Hepat; 2017 Jun; 24(6):486-495. PubMed ID: 28039923
[TBL] [Abstract][Full Text] [Related]
13. Association between rapid utilisation of direct hepatitis C antivirals and decline in the prevalence of viremia among people who inject drugs in Australia.
Iversen J; Dore GJ; Catlett B; Cunningham P; Grebely J; Maher L
J Hepatol; 2019 Jan; 70(1):33-39. PubMed ID: 30367897
[TBL] [Abstract][Full Text] [Related]
14. Liver Health Literacy and Health Status Among Adults With Hepatitis C: Implications for the Nursing Profession as Part of the 2030 Global Elimination Goal.
Lin YC; Chiu WN; Chang TS; Huang TJ; Chen MY
J Nurs Scholarsh; 2020 Mar; 52(2):128-135. PubMed ID: 31750620
[TBL] [Abstract][Full Text] [Related]
15. Microenvironment Eradication of Hepatitis C: A Novel Treatment Paradigm.
Cuadrado A; Llerena S; Cobo C; Pallás JR; Mateo M; Cabezas J; Fortea JI; Alvarez S; Pellón R; Crespo J; Echevarría S; Ayesa R; Setién E; Lopez-Hoyos M; Crespo-Facorro B; Agüero J; Chueca N; Garcia F; Calleja JL; Crespo J
Am J Gastroenterol; 2018 Nov; 113(11):1639-1648. PubMed ID: 29946175
[TBL] [Abstract][Full Text] [Related]
16. ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria.
Schwarz C; Bauer D; Dorn L; Jachs M; Hartl L; Chromy D; Weseslindtner L; Pfisterer N; Hennlich B; Stückler A; Strassl R; Voill-Glaninger A; Hübl W; Willheim M; Köhrer K; Jansen-Skoupy S; Tomez S; Krugluger W; Madl C; Schwarz M; Balcar L; Semmler G; Brinkmann L; Burghart L; Antonitsch L; Weidinger G; Riedl F; Laferl H; Kurteva V; Traugott M; Hind J; Wenisch C; Aburaia A; Sebesta C; Schmid D; Rothweiler S; Remetic J; Gschwantler M; Maieron A; Reiberger T
Wien Klin Wochenschr; 2024 May; 136(9-10):278-288. PubMed ID: 37773541
[TBL] [Abstract][Full Text] [Related]
17. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
Rusch U; Robbins S; Razavi H; Vernazza P; Blach S; Bruggmann P; Müllhaupt B; Negro F; Semela D
Swiss Med Wkly; 2019 Jan; 149():w14694. PubMed ID: 30673118
[TBL] [Abstract][Full Text] [Related]
18. Prior to the oral therapy, what do we know about HCV-4 in Egypt: a randomized survey of prevalence and risks using data mining computed analysis.
Abd Elrazek AE; Bilasy SE; Elbanna AEM; Elsherif AEA
Medicine (Baltimore); 2014 Dec; 93(28):e204. PubMed ID: 25526438
[TBL] [Abstract][Full Text] [Related]
19. Treatment access is only the first step to hepatitis C elimination: experience of universal anti-viral treatment access in Australia.
Doyle JS; Scott N; Sacks-Davis R; Pedrana AE; Thompson AJ; Hellard ME;
Aliment Pharmacol Ther; 2019 May; 49(9):1223-1229. PubMed ID: 30908706
[TBL] [Abstract][Full Text] [Related]
20. Evidence for the elimination of viral hepatitis B and C in Egypt: Results of a nationwide survey in 2022.
Kandeel A; Fahim M; Abukamar S; BahaaEldin H; Abuelsood H; Samy S; Deghedy O; Sheta A; Naguib A; El Guindy N; Youssef A; Kamel R; Afifi S; El-Kassas M; Abdelghaffar K
Liver Int; 2024 Apr; 44(4):955-965. PubMed ID: 38291807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
